THERAPY DOSSIER · th-1dfe2978e73b

Insulin-like growth factor 1 (IGF-1)

Biologic · Recombinant insulin-like growth factor 1; growth-factor protein (mecasermin).

Evidence & regulatory context

Mechanism: Recombinant insulin-like growth factor 1; growth-factor protein (mecasermin).
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01525901 ↗PHASE2completed

Recombinant IGF-1 in 22q13 Deletion (Phelan-McDermid) Syndrome

22q13 Deletion Syndrome · Phelan-McDermid Syndrome

Enrolment: 19 · Results not recorded

NCT00566241 ↗PHASE1terminated

IGF-1 Therapy in Cystic Fibrosis

Cystic Fibrosis

Enrolment: 15 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32863068 ↗2020Reported benefit

Exogenous insulin-like growth factor 1 attenuates acute ischemic stroke-induced spatial memory impairment via modulating inflammatory response and tau phosphorylation.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-Dawleymaleintravenouscommenced 24 h after surgery

Model: Transient occlusion of the left middle cerebral artery (acute ischaemic stroke)

Intravenous IGF-1 raised IGF-1 levels in plasma, ischaemic amygdala, hippocampus and cortex, improved neurological dysfunction and cognitive deficits, reduced cerebral infarction and brain oedema, lowered serum and hippocampal IL-6, IL-1 beta and TNF-alpha, and attenuated hippocampal tau phosphoryl…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…